FAM163A

Across TCGA pan-cancer cohorts, FAM163A Mutation is linked to patient survival in 3 of 34 cancer types, making it a survival-associated FAM163A data layer compared with 23 for mass-spec protein.

The strongest signal is observed in small cell lung cancer (SCLC), where higher FAM163A Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated FAM163A expression acts as an unfavorable survival marker.

SCLC, UCEC, and SKCM are the cancer types where FAM163A Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
SCLC	OS	Median	All	0.301	0.711	.018	12	view →
UCEC	OS	Median	IV	0.231	0.592	.036	6	view →
SKCM	DFS	Median	All	0.317	0.732	.019	2	view →

Pink = unfavorable, green = favorable. Showing the 3 strongest of 3 lineages.

FAM163A–SCLC (OS)

Open the SCLC breakdown →